/PSYGF
PSYGF Stock - Psyence Group Inc.
Healthcare|Drug Manufacturers - GeneralOTC
$0.13+0.00%
+$0.00 (+0.00%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.58
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.70
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.14
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PSYGF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.13 – $0.13
TARGET (TP)$0.15
STOP LOSS$0.12
RISK/REWARD1:3.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.24
52W High$0.40
52W Low$0.07
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-8,460 | $-97,929 | $-92,269 | $-52,636 | $-24,496 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-5,507,274 | $-5,162,046 | $-6,087,950 | $-4,593,624 | $-92,511 |
| Net Income | $-400,230 | $-69,445,310 | $-6,082,292 | $-4,600,766 | $-92,511 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.04 | $-0.52 | $-0.07 | $-0.05 | $-0.00 |
Company Overview
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PSYGFBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q4 2024
EPS Surprise History
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Dec 31, 2024 | — | $-0.01 | — | — |
Q3 2024 | Sep 30, 2024 | — | $0.02 | — | — |
Q2 2024 | Jun 29, 2024 | — | $0.01 | — | — |
Q1 2024 | Mar 30, 2024 | — | $-0.37 | — | — |
Q4 2023 | Dec 31, 2023 | — | $0.00 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.01 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.02 | — | — |
Q1 2023 | Mar 1, 2023 | — | $-0.01 | — | — |
Q4 2022 | Nov 29, 2022 | — | $-0.01 | — | — |
Q3 2022 | Aug 29, 2022 | — | $-0.01 | — | — |
Q3 2022 | Jul 5, 2022 | — | $-0.01 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.01 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.11 | — | — |
Q4 2020 | Dec 30, 2020 | — | $-0.03 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.00 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about PSYGF
What is PSYGF's current stock price?
Psyence Group Inc. (PSYGF) is currently trading at $0.13 per share. The stock has moved +0.00% today.
What is the analyst price target for PSYGF?
No analyst price targets are currently available for this stock.
What sector is Psyence Group Inc. in?
Psyence Group Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the OTC exchange.
What is PSYGF's market cap?
Psyence Group Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does PSYGF pay dividends?
No, Psyence Group Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADXS
Ayala Pharmaceuticals, Inc.
$0.15
Mkt Cap: $0.0B
ANTCF
Aion Therapeutic Inc.
$0.00
Mkt Cap: $0.0B
CRYM
Cryomass Technologies Inc.
$0.00
Mkt Cap: $0.0B
GENPF
Genix Pharmaceuticals Corporation
$0.03
Mkt Cap: $0.0B
IGEX
Indo Global Exchange(s) PTE, Ltd.
$0.00
Mkt Cap: $0.0B
KAYS
Kaya Holdings, Inc.
$0.04
Mkt Cap: $0.0B
KOAN
Resonate Blends, Inc.
$0.00
Mkt Cap: $0.0B
NMLSF
Restart Life Sciences Corp.
$0.08
Mkt Cap: $0.0B
RNUGF
ReNeuron Group plc
$0.00
Mkt Cap: $0.0B
TLLTF
TILT Holdings Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to PSYGF for comparison